×
CNS Pharmaceuticals EBITDA 2019-2024 | CNSP
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
CNS Pharmaceuticals ebitda from 2019 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
CNS Pharmaceuticals EBITDA 2019-2024 | CNSP
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
CNS Pharmaceuticals ebitda from 2019 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$170.3B
Vertex Pharmaceuticals (VRTX)
$122B
Bristol Myers Squibb (BMY)
$112.5B
Gilead Sciences (GILD)
$111.9B
Regeneron Pharmaceuticals (REGN)
$91.4B
CSL (CSLLY)
$90.8B
GSK (GSK)
$76.6B
Argenex SE (ARGX)
$35.2B
Alnylam Pharmaceuticals (ALNY)
$34.8B
BioNTech SE (BNTX)
$25.9B
Biogen (BIIB)
$25.3B
Illumina (ILMN)
$24.5B
Moderna (MRNA)
$20.6B
BeiGene (BGNE)
$20.2B
Genmab (GMAB)
$15.1B
Incyte (INCY)
$14.6B
Exact Sciences (EXAS)
$13.1B
BioMarin Pharmaceutical (BMRN)
$12.6B
Insmed (INSM)
$12.2B
Bio-Techne Corp (TECH)
$12B
Vaxcyte (PCVX)
$11.9B
Sarepta Therapeutics (SRPT)
$11.7B
QIAGEN (QGEN)
$10B
Exelixis (EXEL)
$9.8B
Bio-Rad Laboratories (BIO.B)
$9.3B
Revolution Medicines (RVMD)
$9.3B
Intra-Cellular Therapies (ITCI)
$9.1B
Roivant Sciences (ROIV)
$8.5B
Legend Biotech (LEGN)
$8B
Repligen (RGEN)
$7.8B